FDA rejection
FibroGen CEO Conterno Resigns Amid Roxadustat Launch Setbacks
SG Tylor
Source – FibroGen Enrique Conterno, who became FibroGen’s CEO in early 2020, had high hopes for the anemia drug roxadustat ...
Teva Expands Alvotech Collaboration with 2 New Biosimilar, $40M Investment & Enhanced Oversight
SG Tylor
Source – Teva Pharmaceuticals Following the second FDA rejection of Teva’s Alvotech-partnered biosimilar for Humira, the two companies are expanding ...
